聯康生物科技集團(00690.HK):金因康®(地誇磷索鈉滴眼液)上市申請已經正式獲中國國家藥品監督管理局(NMPA)批準
格隆匯5月21日丨聯康生物科技集團(00690.HK)公告,中國國家藥品監督管理局("NMPA")已於2025年5月21日批準集團的眼科新產品金因康®(地誇磷索鈉滴眼液)的上市申請,批準文號爲"國藥準字H20254149"。金因康®的獲批標誌着集團眼科藥物管線的進一步完善,爲乾眼症患者提供更加多樣化的治療方案。
作爲繼金因舒®後集團佈局的第二款眼科藥物,地誇磷索鈉滴眼液通過激活P2Y2受體刺激淚液及黏蛋白分泌,從根源改善乾眼症患者的淚液層穩定性並修復角膜上皮損傷,適用於診斷爲乾眼並伴有異常淚液相關性角膜上皮缺陷的患者,是乾眼症治療的新一代藥物。
集團位於東莞的新生產基地佈局的吹灌封(BFS)一體化技術及無菌生產線,結合無防腐劑、單劑量包裝設計,以確保藥品質量與便利性。預計金因康®也將成爲首批獲批上市的BFS地誇磷索鈉產品之一。
此外,集團已與原料藥(API)供貨商建立戰略夥伴關係,以低於行業平均水平的成本獲取高質量原材料。集團也已戰略性擴充銷售團隊,整合線上線下渠道資源,覆蓋醫院、藥房及主流電商平臺。從而保證金因康®快速提升市場滲透率和競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.